Tests two drugs together in older adults with memory decline and metabolic syndrome
Tests nasal insulin plus oral semaglutide in older adults with mild memory decline.
Plain-language title generated from the registry record
Registry title: COMMETS- Combination MCI Metabolic Syndrome
Key facts
- Where
- Ramat Gan, IsraelSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 90 years old?
Source: NCT06072963, who can take part
Where in Israel
- Joseph Sagol Neuroscience center, Sheba Medical CenterRamat Gan, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rutgers, The State University of New Jersey
- Trial code
- NCT06072963
- Record updated
- 27 July 2026
- Original description
The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive Impairment), who are enriched for cerebrovascular disease and at high dementia risk. The study will focus on cognitive and biological outcomes, allowing identification of relevant mechanisms.Read full original descriptionShow less
Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study
The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive Impairment), who are enriched for cerebrovascular disease and at high dementia risk. The study will focus on cognitive and biological outcomes, allowing identification of relevant mechanisms.
Inclusion: Diagnosis of MCI (based on a MOCA <27 and a clinical dementia rating scale [CDR] score of 0.5 representing questionable dementia); Diagnosis of MetS -requiring a) abdominal obesity (waist circumference >102cm for men and >88cm for women), and b) glucose intolerance (fasting glucose>110 mg/dL) and at least one of the following-c) dyslipidemia (high triglycerides [>150 mg/dL] and low HDL [<40mg/dL for men and <50 mg/dL for women]), or d) elevated blood pressure (>130/>85 mmHg); Fluent in Hebrew; The study requires an active study partner.
Exclusion: Diabetes (of any type); Diagnosis of dementia and its subtypes, conditions that may directly affect cognition,; short life expectancy or a medical condition that precludes consistent participation in the study,; Taking medications that may affect glucose metabolism (including a GLP-1RA); Medications that may affect glucose metabolism such as corticosteroids; contraindications to either insulin or Semaglutide.